🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

90+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 90 recruiting trials for “hereditary-attr-amyloidosis”

Phase 2RecruitingNCT06649695 ↗

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

👨‍⚕️ Murielle Roussel, MD, CHU Limoges📍 10 sites📅 Started Jul 2025View details ↗
Phase 2RecruitingNCT07079423 ↗

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

🏥 Peking Union Medical College Hospital📍 1 site📅 Started Jun 2025View details ↗
EARLY_Phase 1RecruitingNCT07085559 ↗

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

🏥 Anhui Provincial Hospital📍 1 site📅 Started Jun 2025View details ↗
Phase 2RecruitingNCT06935162 ↗

Teclistamab in Previously Treated AL Amyloidosis

🏥 Peking Union Medical College Hospital📍 1 site📅 Started May 2025View details ↗
Phase 3RecruitingNCT06563895 ↗

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

🏥 Eidos Therapeutics, a BridgeBio company📍 98 sites📅 Started May 2025View details ↗
NARecruitingNCT06699394 ↗

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

👨‍⚕️ Jin Lu, M.D., Peking University People's Hospital📍 2 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06971380 ↗

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

🏥 Polina Stepensky📍 1 site📅 Started Mar 2025View details ↗
NARecruitingNCT06983951 ↗

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

👨‍⚕️ yajing zhang, MD/PhD, Beijing Gaobo Boren Hospital📍 1 site📅 Started Feb 2025View details ↗
NAEnrolling by InvitationNCT07103863 ↗

Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis

👨‍⚕️ wei dong, MD,PHD, Beijing Anzhen Hospital📍 1 site📅 Started Feb 2025View details ↗
RecruitingNCT06855121 ↗

The Norwegian Immunotherapy in Multiple Myeloma Study

🏥 St. Olavs Hospital📍 23 sites📅 Started Jan 2025View details ↗
Phase 3Enrolling by InvitationNCT06679946 ↗

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

👨‍⚕️ Medical Director, Alnylam Pharmaceuticals📍 87 sites📅 Started Dec 2024View details ↗
Phase 1, PHASE2RecruitingNCT06569147 ↗

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

👨‍⚕️ Giada Bianchi, Dana-Farber Cancer Institute📍 1 site📅 Started Nov 2024View details ↗
RecruitingNCT07314268 ↗

ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers

🏥 University of Sao Paulo General Hospital📍 1 site📅 Started Oct 2024View details ↗
Phase 2RecruitingNCT06629818 ↗

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

🏥 Peking Union Medical College Hospital📍 1 site📅 Started Oct 2024View details ↗
RecruitingNCT06458374 ↗

ATTR Cardiac Amyloidosis in a Selected Population

👨‍⚕️ Torstein Hole, MD, PhD, Helse Møre og Romsdal HF and NTNU📍 1 site📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06292780 ↗

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

👨‍⚕️ Clinical Trial Management, Regeneron Pharmaceuticals📍 18 sites📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06420167 ↗

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

👨‍⚕️ Jeffrey Zonder, M.D., Barbara Ann Karmanos Cancer Institute📍 1 site📅 Started Jul 2024View details ↗
NARecruitingNCT06573723 ↗

Institutional Registry of Rare Diseases

👨‍⚕️ Marcelo Serra, PhD, HIBA📍 1 site📅 Started Jul 2024View details ↗
Phase 3RecruitingNCT06022939 ↗

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

👨‍⚕️ Patrick A Hagen, SWOG Cancer Research Network📍 35 sites📅 Started Jul 2024View details ↗
RecruitingNCT06465810 ↗

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

🏥 AstraZeneca📍 53 sites📅 Started Jun 2024View details ↗
← PreviousPage 2 of 5Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →